Science | Nature | Cell | View More
Natural Products
Etoposide
ChemFaces products have been cited in many studies from excellent and top scientific journals
Product Name Etoposide
Price: $50 / 20mg
CAS No.: 33419-42-0
Catalog No.: CFN89061
Molecular Formula: C29H32O13
Molecular Weight: 588.56 g/mol
Purity: >=98%
Type of Compound: Lignans
Physical Desc.: Powder
Source: The herbs of Dysosma versipellis.
Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
Download: COA    MSDS
Similar structural: Comparison (Web)  (SDF)
Guestbook:
Contact Us
Order & Inquiry & Tech Support

Tel: (0086)-27-84237683
Tech: service@chemfaces.com
Order: manager@chemfaces.com
Address: 176, CheCheng Eest Rd., WETDZ, Wuhan, Hubei 430056, PRC
How to Order
Orders via your E-mail:

1. Product number / Name / CAS No.
2. Delivery address
3. Ordering/billing address
4. Contact information
Order: manager@chemfaces.com
Delivery time
Delivery & Payment method

1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

2. We accept: Wire transfer & Credit card & Paypal
Citing Use of our Products
* Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.
According to end customer requirements, ChemFaces provide solvent format. This solvent format of product intended use: Signaling Inhibitors, Biological activities or Pharmacological activities.
Size /Price /Stock 10 mM * 1 mL in DMSO / $14.0 / In-stock
Other Packaging *Packaging according to customer requirements(100uL/well, 200uL/well and more), and Container use Storage Tube With Screw Cap
Our products had been exported to the following research institutions and universities, And still growing.
  • Monash University Sunway Campus (Malaysia)
  • Lund University (Sweden)
  • University of Canterbury (New Zealand)
  • Subang Jaya Medical Centre (Malaysia)
  • Cornell University (USA)
  • Melbourne University (Australia)
  • University of Limpopo (South Africa)
  • Semmelweis Unicersity (Hungary)
  • Sri Ramachandra University (India)
  • The Vancouver Prostate Centre (... (Canada)
  • National Research Council of Ca... (Canada)
  • More...
Package
Featured Products
Gomisin A

Catalog No: CFN98990
CAS No: 58546-54-6
Price: $60/20mg
Silymarin

Catalog No: CFN99542
CAS No: 22888-70-6
Price: $30/20mg
Peimine

Catalog No: CFN99996
CAS No: 23496-41-5
Price: $50/20mg
Tangshenoside I

Catalog No: CFN95108
CAS No: 117278-74-7
Price: $338/10mg
Pallidol

Catalog No: CFN92341
CAS No: 105037-88-5
Price: $318/10mg
Astragaloside IV

Catalog No: CFN99171
CAS No: 84687-43-4
Price: $30/20mg
Rhynchophylline

Catalog No: CFN98131
CAS No: 76-66-4
Price: $98/20mg
Saponarin

Catalog No: CFN90134
CAS No: 20310-89-8
Price: $288/10mg
Uridine

Catalog No: CFN97000
CAS No: 58-96-8
Price: $30/20mg
Ginsenoside Rb1

Catalog No: CFN99964
CAS No: 41753-43-9
Price: $40/20mg
Related Screening Libraries
Size /Price /Stock 10 mM * 100 uL in DMSO / Inquiry / In-stock
10 mM * 1 mL in DMSO / Inquiry / In-stock
Related Libraries
Biological Activity
Description: Etoposide is a chemotherapy medication used for the treatments of a number of types of cancer. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA, it induces apoptosis in MCF-7 breast cancer cells.
Targets: Topoisomerase | Caspase
In vitro:
Cancer Res. 2001 Jan 1;61(1):348-54.
Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis.[Pubmed: 11196185]
MCF-7, a breast cancer-derived cell line, is deficient of caspase 3 and relatively insensitive to many chemotherapeutic agents.
METHODS AND RESULTS:
To study the association of caspase 3 deficiency and chemotherapeutic resistance, we reconstituted caspase 3 in MCF-7 cells and characterized their apoptotic response to doxorubicin and Etoposide. Western blots demonstrated that caspase 3 was constitutively expressed in the reconstituted MCF-7 cells. Both morphological observation and survival assays showed that caspase 3 reconstitution significantly sensitized MCF-7 cells to both drugs. Remarkably increased activation of caspases 3, 6, and 7, cleavage of cellular death substrates, and DNA fragmentation were detected in the reconstituted MCF-7 cells after drug treatment.
CONCLUSIONS:
Together, these data demonstrated a specific role for caspase 3 in chemotherapy-induced apoptosis and in activation of caspases 6 and 7. Our results also suggest that caspase 3 deficiency may contribute to chemotherapeutic resistance in breast cancer.
In vivo:
Endocr Relat Cancer. 2005 Sep;12(3):657-66.
Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial.[Pubmed: 16172198]

METHODS AND RESULTS:
To investigate the activity of Etoposide, doxorubicin, and cisplatin plus mitotane in the management of advanced adrenocortical carcinoma (ACC) patients, 72 patients with measurable disease not amenable to radical surgery were enrolled in a prospective, multicenter phase II trial. EDP schedule (Etoposide 100 mg/m(2) on days 5-7, doxorubicin 20 mg/m(2) on days 1 and 8, and cisplatin 40 mg/m(2) on days 1 and 9) was administered intravenously every 4 weeks. Concomitantly, patients were given up to 4 g/day of oral mitotane. Five patients achieved a complete response and 30 a partial response, for an overall response rate of 48.6% (95% CI: 37.1-60.3). Median time to progression in responding patients was 18 months. The EDP regimen was well tolerated, leukopenia being the dose limiting toxicity. One toxic related death due to septic shock, however, was registered. Radical surgical resection of residual disease after chemotherapy was performed in 10 patients. The overall survival of patients attaining a disease free status (clinical complete responders+radically resected) was significantly higher than that of patients with partial response or no response (P<0.002). Androgen secretion was associated with long survival, while glucocorticoid secretion was associated with poor prognosis both in univariate and multivariate analysis.
CONCLUSIONS:
In conclusion, EDP plus mitotane is an active and manageable combination scheme for ACC patients. Surgical resection of residual disease subsequent to chemotherapy leads to a more favourable outcome. The natural history of the disease is significantly influenced by the secretory status of the tumor.
J Clin Oncol. 2000 Mar;18(6):1173-80.
Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients.[Pubmed: 10715285 ]
To evaluate the efficacy and toxicity of sequential, dose-intensified chemotherapy with paclitaxel/ifosfamide and carboplatin/Etoposide administered plus peripheral blood-derived stem-cell (PBSC) support for patients with germ cell tumors (GCT) who have unfavorable prognostic features in response to conventional-dose salvage programs. Carboplatin was dose escalated by target area under the curve (AUC; in [milligrams per milliliter] x minutes) among patient cohorts, and pharmacokinetic studies were performed for comparison.
METHODS AND RESULTS:
Thirty-seven previously treated patients who had cisplatin-resistant GCT and unfavorable prognostic features for response to conventional-dose salvage therapy were treated. Two cycles of paclitaxel 200 mg/m(2) plus ifosfamide 6 g/m(2) were given 2 weeks apart with leukapheresis, followed by three cycles of carboplatin plus Etoposide given 14 to 21 days apart with reinfusion of PBSCs. The dose of Etoposide was 1, 200 mg/m(2), and the carboplatin target AUC ranged among cohorts from 12 to 32 (mg/mL) x min. Pharmacokinetic studies of carboplatin were performed for comparison of target to measured AUC. Twenty-one patients (57%) achieved a complete response and an additional two patients (5%) achieved a partial response with normal tumor markers; therefore, 23 (62%) achieved a favorable response. Eight patients relapsed, and 15 (41%) of the favorable responses remained durable at a median follow-up of 30 months. Myelosuppression was the major toxicity; 58% of carboplatin/Etoposide cycles were associated with hospitalization for nadir fever. The AUC of carboplatin measured in serum was lower than the target AUC; this may be related to underestimation of the glomerular filtration rate used in the dosing formula.
CONCLUSIONS:
Dose-intense therapy with sequential, accelerated chemotherapy of paclitaxel/ifosfamide and carboplatin/Etoposide administered with PBSC support was relatively well tolerated. The durable complete response proportion was substantial in patients with unfavorable prognostic features for achieving durable complete response to conventional-dose salvage programs. Optimal dosing of carboplatin in the high-dose setting warrants further investigation.
Leuk Lymphoma. 1994 Sep;15(1-2):127-30.
Idarubicin, high-dose cytarabine and etoposide for remission induction in therapy-related acute myeloid leukemia[Pubmed: 7858489 ]

METHODS AND RESULTS:
Five patients with therapy-related acute myeloid leukemia received combination induction chemotherapy with idarubicin, high-dose cytarabine, and Etoposide. Complete remission was achieved in all patients with a single course of therapy. Treatment-related toxicity included nausea, vomiting, mucositis, diarrhea, and liver and kidney function abnormalities, and was low in all patients. There were no deaths during induction therapy.
CONCLUSIONS:
We conclude that this combination is well-tolerated in induction of remission in secondary acute myeloid leukemia, and warrants further assessment because of a very good complete remission rate.
Etoposide Description
Source: The herbs of Dysosma versipellis.
Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
Storage: Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

After receiving: The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
ChemFaces New Products and Compounds
Isorhamnetin 3,5-O-diglucoside

Catalog No: CFN95488
CAS No: 2035413-03-5
Price: $318/10mg
Marginatoxin

Catalog No: CFN95174
CAS No: 1422536-56-8
Price: $318/10mg
Quercetin 3,7-diglucoside

Catalog No: CFN95408
CAS No: 6892-74-6
Price: $318/10mg
Taxezopidine H

Catalog No: CFN95562
CAS No: 205440-23-9
Price: $318/5mg
Cannabisin P

Catalog No: CFN95456
CAS No: 2756983-19-2
Price: $318/5mg
Sphenanlignan

Catalog No: CFN95245
CAS No: 866347-36-6
Price: $318/5mg
Orientalide

Catalog No: CFN95136
CAS No: 72704-05-3
Price: $368/5mg
4-Hydroxybenzoyl choline

Catalog No: CFN95158
CAS No: 5094-31-5
Price: $318/20mg
Recently, ChemFaces products have been cited in many studies from excellent and top scientific journals

Cell. 2018 Jan 11;172(1-2):249-261.e12.
doi: 10.1016/j.cell.2017.12.019.
IF=36.216(2019)

PMID: 29328914

Cell Metab. 2020 Mar 3;31(3):534-548.e5.
doi: 10.1016/j.cmet.2020.01.002.
IF=22.415(2019)

PMID: 32004475

Mol Cell. 2017 Nov 16;68(4):673-685.e6.
doi: 10.1016/j.molcel.2017.10.022.
IF=14.548(2019)

PMID: 29149595

ACS Nano. 2018 Apr 24;12(4): 3385-3396.
doi: 10.1021/acsnano.7b08969.
IF=13.903(2019)

PMID: 29553709

Nature Plants. 2016 Dec 22;3: 16206.
doi: 10.1038/nplants.2016.205.
IF=13.297(2019)

PMID: 28005066

Sci Adv. 2018 Oct 24;4(10): eaat6994.
doi: 10.1126/sciadv.aat6994.
IF=12.804(2019)

PMID: 30417089
Calculate Dilution Ratios(Only for Reference)
1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 1.6991 mL 8.4953 mL 16.9906 mL 33.9812 mL 42.4766 mL
5 mM 0.3398 mL 1.6991 mL 3.3981 mL 6.7962 mL 8.4953 mL
10 mM 0.1699 mL 0.8495 mL 1.6991 mL 3.3981 mL 4.2477 mL
50 mM 0.034 mL 0.1699 mL 0.3398 mL 0.6796 mL 0.8495 mL
100 mM 0.017 mL 0.085 mL 0.1699 mL 0.3398 mL 0.4248 mL
* Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
Protocol
Kinase Assay:
Eur J Cancer. 1998 Sep;34(10):1514-21.
Etoposide: four decades of development of a topoisomerase II inhibitor.[Pubmed: 9893622]
Podophyllin-containing materials have been used as folk medicines for centuries. In the 1950s, scientists began a search to identify a more effective podophyllotoxin derivative. These efforts eventually resulted in the development of a new class of antineoplastic agents which target the DNA unwinding enzyme, topoisomerase II.
METHODS AND RESULTS:
The history of the development of one of the first identified topoisomerase II inhibitors, Etoposide, is reviewed in this paper. Critical developments in Etoposide's mechanism of action, pharmacology and administration schedule are summarised. The clinical benefits of the recently marketed Etoposide prodrug, Etoposide phosphate (Etopophos) are also detailed. The current status of other clinically approved anticancer agents which target topoisomerase II is briefly reviewed.
Gomisin A

Catalog No: CFN98990
CAS No: 58546-54-6
Price: $60/20mg
Silymarin

Catalog No: CFN99542
CAS No: 22888-70-6
Price: $30/20mg
Peimine

Catalog No: CFN99996
CAS No: 23496-41-5
Price: $50/20mg
Tangshenoside I

Catalog No: CFN95108
CAS No: 117278-74-7
Price: $338/10mg
Pallidol

Catalog No: CFN92341
CAS No: 105037-88-5
Price: $318/10mg
Astragaloside IV

Catalog No: CFN99171
CAS No: 84687-43-4
Price: $30/20mg
Rhynchophylline

Catalog No: CFN98131
CAS No: 76-66-4
Price: $98/20mg
Saponarin

Catalog No: CFN90134
CAS No: 20310-89-8
Price: $288/10mg
Uridine

Catalog No: CFN97000
CAS No: 58-96-8
Price: $30/20mg
Ginsenoside Rb1

Catalog No: CFN99964
CAS No: 41753-43-9
Price: $40/20mg
Tags: buy Etoposide | Etoposide supplier | purchase Etoposide | Etoposide cost | Etoposide manufacturer | order Etoposide | Etoposide distributor